About Conjustar


ConjuStar Biologics jointly incubated by FOSUN health capital New Drug Fund and WuXi AppTec, and is dedicated to the development of novel miniaturized conjugated drugs (peptide/nanobody-conjugated drugs (PDC/NDC)).

Our mission is to develop tumor-penetrating drugs that address unmet clinical needs. The PDC platform represents the next-generation XDC modality.

 

 

MORE+

Investor Relations

News

MORE+

Technology Platform

Conjustar has the globally excellent technology platform of Development of novel miniaturized conjugated drugs (peptide/nanobody conjugated drugs, PDC/NDC).

MORE+

Pipeline

We successfully secured approximately $40 million in financing, which has enabled us to rapidly progress five oncology pipelines.

MORE+

BD and Licensing

Business development is a strategic function of Conjustar, responsible for the portfolio strategy of the Company’s innovation pipeline as well as the planning, development and implementation of partnering strategy.

MORE+